p38-MAPK and CDK5, signaling pathways in neuroinflammation:a potential therapeutic intervention in Alzheimer’s disease?

Vlad Ionut Viorel, Ylenia Pastorello, Nosherwan Bajwa, Mark Slevin

Recent advancements suggest a potential interplay between the p38 MAPK and CDK5 signaling pathways, providing a novel therapeutic intervention in AD.The roles of these pathways have been validated using advanced techniques like single-cell sequencing and neuroimaging,adding more depth to our understanding.The advancement of novel therapies targeting these pathways, such as small molecule inhibitors and gene therapies, has shown promising results in preclinical studies and early-phase clinical trials.This perspective will summarize the molecular interconnections between p38 MAPK and CDK5, providing our personal viewpoint on the relevance of specifically directed and/or multiple simultaneous signal abrogation in future treatment strategies.

p38-MAPK’s role and impact in AD: The MAPKs are a pivotal class of serine/threonine protein kinases that manage numerous cellular functions,including cell growth, differentiation, survival, and apoptosis (Guo et al., 2020).In the context of AD,the p38 MAPK signaling pathway has a significant impact, especially in neuroinflammation, being a critical factor in the disease progression.For example, its activation within microglia has been identified as a significant contributor to the upregulation of proinflammatory cytokines,via nuclear factor kappa B dependent-signaling pathway, particularly in response to Aβ or Toll-like receptor ligands.Vascular dysfunction is another critical aspect of AD pathophysiology, with evidence also suggesting the involvement of the p38 MAPK signaling pathway.Specifically, this pathway stimulates aberrant endothelial cell activation, increasing gap-junctions and impacting the permeability of the blood-brain barrier (BBB) promoting immune cell transmigration, barrier dysfunction, and subsequently escalating micro-environmental neuroinflammation (Wang et al., 2020)

CDK5 and aberrant signaling associated with acute and chronic neuroinflammation: CDK5 is an atypical cyclin-dependent kinase that helps to maintain the functional integrity of the neurovascular unit (NVU) and the BBB, by regulating vascular patency and neuroglial activity.However, its hyperphosphorylated, dysregulated activation, particularly through p25-CDK5 preferential binding, compromises the NVU’s structure, impairs the normal physiological status of the glial vascular unit, and predisposing an individual to AD (Ao et al., 2022).

Quan et al.(2019) showed that lentiviral upregulation of CDK5 increased Aβ production and concomitant apoptosis in primary rat hippocampal neurons in a peroxisome proliferator-activated receptor γ-dependent mechanism, whilst Pao et al.(2023) inhibited CDK5/p25 activity using a novel peptide, blocking this interaction and consequently protecting CA1 hippocampal neurons from gliosis and cell death in a p25-inducible murine model.Most recently, both the concept of vascular aberration and neuroinflammatory alignment with AD have been supported by increasing recognition of the correlation between inflammatory cytokine expression and signaling, and the development of neurocognitive disturbances.Wong-Guerra et al.(2023), recently described this, indicating the importance of the cyclic microglial activation pathways perpetuated by the interleukin-6 (IL-6)-CDK5/p35 axis (Figure 1).

CDK5-p38-MAPK interactions in AD: To define the role of CDK5 in mediating inflammatory activation within the central nervous system,we should understand more fully, the complex signaling interactions within individual critical components of the NVU.Recently, Posada-Duque et al.(2021) eloquently summarised the current knowledge pertaining to the importance of CDK5 in maintaining competent NVU and BBB function through control of vascular patency and neuroglial activity.They further described how aberrant overactivation, associated with p25-CDK5 preferential binding compromises the integrity of the NVU, predisposing to potential development of AD.Finally, they contemplated the therapeutic strategies that could protect or improve neuroplasticity by blocking the hyperphosphorylation of CDK5.Two decades ago, Otth et al.(2003) first showed a correlation between phosphorylation of p38, CDK5 overactivation, their co-immunoprecipitation, and expression of Aβ in neuritic plaques of a transgenic murine model of dementia.Quintanilla et al.(2004)demonstrated that exogenous addition of IL-6 to rat hippocampal neurons caused CDK5-dependant increase p38 phosphorylation concomitant with tau phosphorylation.These early studies first indicated a strong relationship between these molecules, induction of inflammation, and dementia.

Figure 1 ｜Legend-microglial CDK5 pathway signaling through MAP kinase P38 in microglia.

Recently, He et al.(2022) provided evidence that modulation of CDK5 could reduce microglial expression of IL-6, as well as other proinflammatory markers (tumor necrosis factor α and IL-1β) in a rat model of intracerebral hemorrhage,indicating a probable role for CDK5 in microglial neuroinflammatory response to injury.Using a rat model of thermal hyperalgesia, Fang-Hu et al.(2015) effectively reduced tumor necrosis factor-α/microglia mediated inflammatory pain by blocking CDK5-p38 signaling, whilst Tomov et al.(2019)inhibited CDK5 using roscovitine, and successfully protected intracerebral dopaminergic grafts from rejection by abrogating local micro-environmental microglial recruitment and activation.The above studies indicate the importance of microglialinduced neuroinflammation in brain disease and reflect the key role of CDK5 in controlling inflammatory status through MAPK signaling,thereby suggesting an important contribution during dysregulation associated with dementia/AD, and possibly other neurocognitive disorders.Since calpain is the primary stimulator for p35 conversion to p25 during calcium deregulated,and other neuroinflammatory associated injury,it is necessary to characterize its relationship to neuronal microglial inflammation, (the source of the majority of neuroinflammation), and associated signaling pathways.Current evidence suggests that astrocyte reactivity is dependent upon calpain-induced p38-MAPK signaling mediated by p25-CDK5.p38-MAPK activation is also associated with decreased synaptic activity,neuronal dysfunction, and neurodegeneration,therefore, regulation of the calpain-p38-p25-CDK5 axis could represent an important neuroprotective strategy.In addition to triggering the inflammatory cascade in neuroglia, aberrant CDK5 activity has direct neurotoxic effects, for example stimulating p38 phosphorylation and reactive oxygen species formation in the presence of glutamate or Aβ,whilst in diabetic mice exposed to high glucose,increased cleavage of p35 by calpain resulted in caspase-3 dependant neuronal apoptosis, which was protected by pre-treatment with the CDK5 inhibitor roscovitine, concomitant with reduction in p38-MAPK expression (Figure 1).

Potential therapeutic approaches in AD targeting CDK5 mediated p38 MAPK activation:Combination therapy, targeting both CDK5 and alternatively activated p38 MAPK pathways that promote glial-induced local neuro-inflammation,could prove to be an effective therapeutic strategy.Given the multifaceted roles these kinases play in AD, a combined inhibition approach might enhance therapeutic effectiveness, minimize side effects, and prevent drug resistance.Blocking p38α signaling could synergistically abrogate feed-forward stimulation of further calpain activity, in addition to nuclear transcription associated with neuroinflammatory cytokine production, and ultimately Aβ dissolution.An example of this multi-kinase inhibition approach is HSB13.This compound, part of the 1,4-benzoxazines class, has demonstrated protective effects against neurodegeneration in a Drosophila model of AD.HSB13 operates by inhibiting a range of kinases associated with AD progression, including glycogen synthase kinase 3, cyclin-dependent kinases (CDKs) 1, 2, and 5,and p38 MAPK.The inhibition of these kinases,identified via kinase profiling analyses, suggests a mechanism through which HSB13 confers its neuroprotective effect.

Future perspectives: Future research should focus on overcoming these challenges, refining our understanding of these kinases in the context of AD, and perfecting the pharmacological strategies aimed at their modulation.With continuous advancements in drug discovery, gene therapy, and our increasing understanding of neurodegenerative processes, we should identify more effective treatment strategies against AD.The focus on CDK5 and p38 MAPK reflects the growing recognition that combating AD will require multifaceted therapeutic strategies that target not just a single molecule or process, but the intricate network of biological systems, and in particular the key or primary signaling units that contribute to disease progression.

本文以零件配套生產(chǎn)問題為例，研究了針對生產(chǎn)資源的不同屬性多角度地選擇決策變量來建立優(yōu)化生產(chǎn)模型的方法，為企業(yè)管理者提供更多的生產(chǎn)決策依據(jù)，通過實(shí)例數(shù)據(jù)及其求解也驗(yàn)證了三種模型及其優(yōu)化生產(chǎn)方案的有效性，同時也指出了各自的優(yōu)缺點(diǎn)．企業(yè)管理者可以根據(jù)本企業(yè)的實(shí)際情況合理的選取生產(chǎn)方案．

One of the critical goals should be to block aberrant microglial stimulation associated with either systemic or brain localized trauma.However,since normal glial communication with the glial vascular unit and NVU, is required for maintenance of BBB function and neuronal synaptic activity,silencing of primary cell signaling pathways is not an acceptable form of therapeutic.Therefore,the selection of more specific intermediates, or indeed a pathway set such as calpain-CDK5-p38α as described above, where cycling and feedback can result in chronic activation and incremental neurodegenerative effects, e.g.specific agonists like calpain and IL-6, could synergistically and more effectively protect against neuroinflammatory associated dementia.

Vlad Ionut Viorel, Ylenia Pastorello,Nosherwan Bajwa, Mark Slevin*

George Emil Palade University of Medicine,Pharmacy, Science and Technology, Targu Mures,Romania (Viorel VI)

Department of Anatomy and Embryology, George Emil Palade University of Medicine, Pharmacy,Science and Technology, Targu Mures, Romania(Pastorello Y)

DIAKO Hospital, Flensburg, Germany (Bajwa N)Center for Advanced Medical and Pharmaceutical Research (CCAMF), George Emil Palade University of Medicine, Pharmacy, Science and Technology,Targu Mures, Romania (Slevin M)

Manchester Metropolitan University, Manchester,UK (Slevin M)

*Correspondence to:Mark Slevin, PhD,mark.slevin@umfst.ro.

https://orcid.org/0000-0003-3767-4861(Mark Slevin)

Date of submission:July 3, 2023

Date of decision:September 18, 2023

Date of acceptance:October 20, 2023

Date of web publication:December 11, 2023

https://doi.org/10.4103/1673-5374.389645

How to cite this article:Viorel VI,Pastorello Y,Bajwa N,Slevin M(2024)p38-MAPK and CDK5,signaling pathways in neuroinflammation:a potential therapeutic intervention in Alzheimer’s disease?Neural Regen Res 19(8):1649-1650.

Open access statement:This is an open access journal,and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License,which allows others to remix,tweak,and build upon the work non-commercially,as long as appropriate credit is given and the new creations are licensed under the identical terms.